Analyst Reco. BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
27.03 ^USD	+5.50%		+6.17%	-33.04%

07/04	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
20/03	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	20/03	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	19/03	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	11/03	MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating	04/03	MT
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating	23/02	MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating	23/02	MT
HC Wainwright Raises BridgeBio Pharma Price Target to $47 From $22, Maintains Buy Rating	29/01	MT
JPMorgan Adjusts BridgeBio Pharma Price Target to $35 From $38, Maintains Overweight Rating	24/11	MT
Citigroup Starts BridgeBio Pharma With Buy Rating, $42 Price Target	07/11	MT
BridgeBio Pharma Says Heart Disease Drug Showed 81% Survival Rate in Phase 3 Study	28/23/28	MT
JPMorgan Adjusts Price Target on BridgeBio Pharma to $38 From $42, Maintains Overweight Rating	17/23/17	MT
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Buy Rating	14/23/14	MT
Raymond James Raises Price Target on BridgeBio Pharma to $46 From $29, Maintains Outperform Rating	18/23/18	MT
Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	18/23/18	MT
Jefferies Downgrades BridgeBio Pharma to Hold From Buy, Adjusts Price Target to $33 From $24	18/23/18	MT
Mizuho Hikes Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	18/23/18	MT
In wait-and-see mode before Tesla and Netflix	17/23/17
Mizuho Securities Adjusts BridgeBio Pharma Price Target to $29 From $23, Maintains Buy Rating	08/23/08	MT
Evercore ISI Starts BridgeBio Pharma at Outperform With $40 Price Target	19/23/19	MT
SVB Securities Raises Price Target on BridgeBio Pharma to $27 From $25, Keeps Outperform Rating	13/23/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Analyst Reco.

Filters